Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants

              Author:Hincelin-Mery, Agnes   Lewanczyk, Pascale   Cantalloube, Cathy   Nicolas, Xavier   Benamor, Myriam   Pomponio, Robert   Krupka, Emmanuel   Ofengeim, Dimitry   Eastenson, Amy   Xiong, Li   Atassi, Nazem   

              Session Name:S46: MS Therapeutics and Clinical Decision Making  

              Topic:MS and Inflammatory Disease  

              Program Number:S46.005  

              Author Institution:Sanofi, Chilly-Mazarin, France  Ividata Life Sciences, Levallois-Perret, France  Sanofi, Montpellier, France  Sanofi, Cambridge, MA  Nucleus Network Pty Ltd, St Paul, MN